Omega-3-acid ethyl esters (Lovaza)
Small molecule
Evidence outlook
Approved: Severe Hypertriglyceridemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
No registered study from this product's approval programme in this use was found on ClinicalTrials.gov.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (27)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (4)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Severe Hypertriglyceridemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Omega-3-Acid Ethyl Esters (Lovaza): this drug | Approved | Small molecule | Triglyceride metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | Reliable signal | NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3) | |
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 | Reliable signal | NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | |
| Omega-3-Acid Ethyl Esters A (Omtryg) | ApprovedUS marketing discontinued | Small molecule | Triglyceride synthesis / VLDL | not yet graded | No reviewed efficacy summary in this indication | |
| DR10624 | Phase 3 | Protein / enzyme therapeutic | GLP-1R; GCGR; FGF21R | Partial signal | NCT06555640: Median triglyceride reduction: 74.5% (12.5 mg), 66.2% (25 mg), 68.9% (50 mg titration) vs 8.0% with placebo | |
| Pegozafermin | Phase 3 | Protein / enzyme therapeutic | FGFR1c/2c/3c–β-Klotho agonist | Partial signal | No reviewed efficacy summary in this indication | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Partial signal | NCT03011450: Percent Change in Fasting TG From Baseline to Week 12 (12 Weeks): K-877 -58.89% (IQR -71.69 to -38.42) vs Placebo -22.94% (IQR -43.98 to 9.67) NCT03001817: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 (12 Weeks): K-877 -56% (IQR -72.08 to -32.4) vs Placebo -7.97% (IQR -44.78 to 49.87) | |
| Plozasiran (Redemplo) | Phase 3 | RNA / oligonucleotide | APOC3 | Partial signal | No reviewed efficacy summary in this indication | |
| Volanesorsen (Waylivra) | Phase 3 | RNA / oligonucleotide | APOC3 mRNA | Partial signal | NCT02300233: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Volanesorsen Total -71.2% (95% CI -79.3 to -63.2) vs Placebo -0.9% (95% CI -13.9 to 12.2) | |
| HRS-7249 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| SEFA-1024 | Phase 2(overall) | Small molecule | Hepatic triglyceride/VLDL synthesis pathway | Partial signal | No reviewed efficacy summary in this indication | |
| Solbinsiran | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| CS-121 | Phase 1 | Gene therapy / editing | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| CTX310 | Phase 1 | Gene therapy / editing | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| GC304 | Phase 1(overall) | Gene or cell therapy (subtype unspecified) | LPL (lipoprotein lipase) gene | not yet graded | No reviewed efficacy summary in this indication | |
| Extended-Release Niacin (Niaspan) | Discontinued | Small molecule | GPR109A (HCAR2) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Omega-3-acid ethyl esters (Lovaza) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.